Moreover, loss-of-function mutations of GBA1 are a major cause of hereditary Parkinson’s Disease (PD), while the activation of beta-GCase increases alpha-synuclein clearance and lysosomal function in dopaminergic neurons (Schapira, 2015; Mazzulli et al., 2016; Stojkovska et al., 2018); thus, there may be a risk of PD with GBA1 inhibitors. Here, SNCA is linked to Parkinson disease.